Skip to main content

Table 1 Baseline characteristics of the entire cohort (N = 149)

From: Cytoreductive radiotherapy combined with abiraterone in metastatic castration-resistance prostate cancer: a single center experience

Characteristics No. (%)
Age, median (range), years 68 (45–86)
PSA at mCRPC  
 ≤ 20 ng/mL 80 (53.7)
 > 20 ng/mL 69 (46.3)
Gleason scorea  
 ≤ 8 70 (47.0)
 9–10 79 (53.0)
ECOG  
 0–1 105 (70.5)
 > 1 44 (29.5)
Prognostic indexb  
 Good 65 (43.6)
 Intermediate 75 (50.3)
 Poor 9 (6.0)
Synchronous metastasis 127 (85.2)
Oligometastasis 58 (38.9)
Chemo-naïve 123 (82.6)
  1. PSA prostate-specific antigen, mCRPC metastatic castration-resistant prostate cancer, Chemo-naïve chemotherapy-naïve upon abiraterone treatment
  2. aGleason score at diagnosis of prostate cancer
  3. bThe COU-AA-301 prognostic index